CiMaas BV

CiMaas is a start-up biotech company (spin-off from Maastricht University) focused on the development of immune cell therapy for cancer patients. The company’s lead products are a dendritic cell vaccine that is ready to be validated and tested in clinical trials and natural killer (NK) cells obtained from healthy donors that have already proven in rodent studies to demonstrate great anti-tumor activity.

CiMaas develops a dendritic cell vaccine for lung cancer patients and for multiple myeloma patients, both high-unmet medical need indications. CiMaas has a developed a proprietary maturation procedure that is expected to produce a highly effective dendritic cell product.

NK cells will be produced by CiMaas using a specific device that allows for production of high numbers of these cells needed in patients with cancer.

CiMaas is building up an immune therapy pipeline to develop this technology. This pipeline might partly be based on R&D activities performed at the MUMC+, Maastricht, the Netherlands. Initiatives of other institutes in the field of cell therapy in cancer will also be explored.